Bristol Finds Biomarkers For Improved Response To Orencia In RA
This article was originally published in The Pink Sheet Daily
Rheumatoid arthritis patients treated with Bristol’s Orencia who tested positive for two biomarkers of poor prognosis had a significantly greater response on outcomes than those who did not in a real-world data analysis presented at EULAR. The experience with TNF inhibitors was different.
You may also be interested in...
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.